Logo
Home
Company ProfileBoards & StaffsMemberships & PartnersAcademy of JournalismCareersBlog(EN)Contact Us
Our JournalsInstruction for AuthorsBrieflands PoliciesPublish My ResearchJournal Management SystemArticle Processing ChargesOpen Peer ReviewPublishing Services
Publish My Book
  1. Brieflands
  2. journals
  3. Koomesh
  4. Articles

  5. Prophylactic effect of misoprostol versus tranexamic acid in conjunction with oxytocin in reduction of post-partum hemorrhage after cesarean sectionin: A randomized clinical trial
  6. Scopus by Title (Ref)

Koomesh

Journal of Semnan University of Medical Sciences

Home
Current IssueArchiveIn PressAccepted ManuscriptsSearch
Instructions
Journal InformationEditors & BoardsIndexing and Listing SourcesJournal MetricsOpen Peer Review (OPR)Publication Ethics and Publication Malpractice StatementReviewer and AE Registration FormSupportContact Us
APC
Authors GuideSubmit Manuscript

Scopus by Title (Ref)


1. The Effect of Oral and Intravenous Tranexamic Acid on Reducing the Incidence of Postpartum Hemorrhage after Cesarean Section: A Randomized Controlled Clinical Trial

- Darzi S. , et al.

2. Tranexamic acid for preventing postpartum haemorrhage after vaginal birth

- Rohwer C. , et al.

3. Tranexamic acid for preventing postpartum haemorrhage after caesarean section

- Rohwer C. , et al.

4. Tranexamic acid versus misoprostol for management of postpartum hemorrhage: A systematic review and meta-analysis of randomized controlled trials

- Abu-Zaid A. , et al.

HomeInstructionsAPC

Articles

  • Current Issue
  • Archive
  • In Press
  • Accepted Manuscripts
  • Search

About Journal

  • Journal Information
  • Editors & Boards
  • Indexing and Listing Sources
  • Journal Metrics
  • Open Peer Review (OPR)
  • Publication Ethics and Publication Malpractice Statement
  • Reviewer and AE Registration Form
  • Support
  • Contact Us
Support
Submit a Ticket
BrieflandsBrieflands

Science, Technical, Medical Publisher, Since 2007

All rights reserved by Brieflands, 2026.

Powered by Neoscriber.